Back to GSKView full pipeline
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
Drug Information
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Regulatory Approvals
EMA3/27/2011
Trobalt
Trobalt is indicated as adjunctive treatment of drug-resistant partial-onset seizures with or without secondary generalisation in patients aged 18 years or older with epilepsy, where other appropriate drug combinations have proved inadequate or have not been tolerated.
View on EMADrug Science
Mechanism of action & safety profile
Related Pipeline
Combined Hepatitis A and B vaccinePhase 3
Hepatitis B
GSK Biologicals' Meningococcal vaccine GSK134612 (Nimenrix)Phase 3
Infections, Meningococcal
62.5/25mcgPhase 3
Pulmonary Disease, Chronic Obstructive
FluoridePhase 3
Dental Caries
Haemophilus influenzae type b- and meningococcal (vaccine)Phase 3
Haemophilus Influenzae Type b
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts